Early diagnosis of cancer is critically important for the ideal prognosis of cancer patients. cfDNA-based new technologies have the potential to be the methodology for liquid biopsy of early cancer patients. Dr Xu Songxiao of Zhejiang Cancer Hospital discusses the progress of cfDNA methylation, fragmentome and microbiome studies, as well as the combined application of current biomarkers in this talk at RED 2024.